Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Tuesday

Key Points

• Rhythm Pharmaceuticals is set to release its Q2 2025 earnings results on August 5th, with analysts predicting an earnings loss of ($0.64) per share and revenue of $43.72 million.
• In its last earnings report, Rhythm missed estimates, reporting a loss of ($0.81) per share and revenue of $37.72 million, highlighting a negative net margin of 123.26%.
• The stock price is currently at $85.68, with multiple analysts maintaining a "buy" rating and setting target prices between $80 and $95.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $43.72 million for the quarter.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The company had revenue of $37.72 million for the quarter, compared to the consensus estimate of $40.43 million. During the same quarter in the previous year, the firm posted ($2.35) EPS. The business's revenue for the quarter was up 25.9% compared to the same quarter last year. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM traded up $3.07 on Friday, hitting $88.30. 666,964 shares of the company were exchanged, compared to its average volume of 901,449. The company's 50 day moving average price is $72.39 and its two-hundred day moving average price is $62.45. Rhythm Pharmaceuticals has a one year low of $40.61 and a one year high of $94.80. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of -31.42 and a beta of 2.38.

Insider Activity

In related news, insider Alastair Garfield sold 1,319 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $64.81, for a total value of $85,484.39. Following the transaction, the insider owned 3,126 shares in the company, valued at $202,596.06. This trade represents a 29.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Christopher Paul German sold 3,817 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $80.75, for a total transaction of $308,222.75. Following the completion of the transaction, the chief accounting officer owned 922 shares in the company, valued at $74,451.50. This represents a 80.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 81,417 shares of company stock valued at $6,352,511. Corporate insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

An institutional investor recently raised its position in Rhythm Pharmaceuticals stock. AQR Capital Management LLC boosted its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 148.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,363 shares of the company's stock after buying an additional 23,506 shares during the period. AQR Capital Management LLC owned approximately 0.06% of Rhythm Pharmaceuticals worth $2,085,000 as of its most recent SEC filing.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RYTM. HC Wainwright reissued a "buy" rating and issued a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 8th. Stifel Nicolaus upped their target price on shares of Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Canaccord Genuity Group upped their target price on shares of Rhythm Pharmaceuticals from $92.00 to $105.00 and gave the company a "buy" rating in a research note on Friday, July 18th. Wells Fargo & Company upped their target price on shares of Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, JMP Securities reissued a "market outperform" rating and issued a $84.00 target price on shares of Rhythm Pharmaceuticals in a research note on Thursday, June 26th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $91.93.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.